BACKGROUND: Empirical evidence suggests that there is a significant genetic influence in the development of posttraumatic stress disorder (PTSD). The serotonin transporter (5-HTT) gene (SLC6A4) has been identified as a prime candidate for the development of the disorder, as 5-HTT is a working target for selective serotonin reuptake inhibitors (SSRIs), first line treatment agents for PTSD. Several studies have reported associations between 5-HTT-linked promoter region (5-HTTLPR) polymorphism variants and increased rates of PTSD in civilian samples. This study investigated the role of the 5-HTTLPR polymorphism, triallelically classified, in a sample of combat veterans with and without PTSD. METHODS: Rates of PTSD were examined across three genotypes in a sample of 388 combat veterans. The short/long polymorphism of 5-HTTLPR and the A-G polymorphism within the 5-HTTLPR (rs25531) were genotyped, and statistical analyses were conducted. RESULTS: There were significant intergroup (PTSD versus non-PTSD) differences in the genotype frequencies of 5-HTTLPR/rs25531 (χ(2) [1, n = 388] = 16.23, P = 5.62 × 10(-5) ). The 5-HTTLPR S'/S' (low transcriptionally efficient) genotype was also associated with the PTSD severity score in the 228 participants who had combat severity data (r = .15, P = 0.03). CONCLUSIONS: The findings are consistent with previous research among civilian populations that have indicated that the low transcriptionally efficient S'/S' genotype of 5-HTTLPR is a risk factor for the development of PTSD after trauma exposure. Our findings are the first to examine this polymorphism and PTSD in a military sample. Additional large-scale investigations are needed to replicate these findings.
BACKGROUND: Empirical evidence suggests that there is a significant genetic influence in the development of posttraumatic stress disorder (PTSD). The serotonin transporter (5-HTT) gene (SLC6A4) has been identified as a prime candidate for the development of the disorder, as 5-HTT is a working target for selective serotonin reuptake inhibitors (SSRIs), first line treatment agents for PTSD. Several studies have reported associations between 5-HTT-linked promoter region (5-HTTLPR) polymorphism variants and increased rates of PTSD in civilian samples. This study investigated the role of the 5-HTTLPR polymorphism, triallelically classified, in a sample of combat veterans with and without PTSD. METHODS: Rates of PTSD were examined across three genotypes in a sample of 388 combat veterans. The short/long polymorphism of 5-HTTLPR and the A-G polymorphism within the 5-HTTLPR (rs25531) were genotyped, and statistical analyses were conducted. RESULTS: There were significant intergroup (PTSD versus non-PTSD) differences in the genotype frequencies of 5-HTTLPR/rs25531 (χ(2) [1, n = 388] = 16.23, P = 5.62 × 10(-5) ). The 5-HTTLPR S'/S' (low transcriptionally efficient) genotype was also associated with the PTSD severity score in the 228 participants who had combat severity data (r = .15, P = 0.03). CONCLUSIONS: The findings are consistent with previous research among civilian populations that have indicated that the low transcriptionally efficient S'/S' genotype of 5-HTTLPR is a risk factor for the development of PTSD after trauma exposure. Our findings are the first to examine this polymorphism and PTSD in a military sample. Additional large-scale investigations are needed to replicate these findings.
Authors: Dean G Kilpatrick; Karestan C Koenen; Kenneth J Ruggiero; Ron Acierno; Sandro Galea; Heidi S Resnick; John Roitzsch; John Boyle; Joel Gelernter Journal: Am J Psychiatry Date: 2007-11 Impact factor: 18.112
Authors: Ananda B Amstadter; Karestan C Koenen; Kenneth J Ruggiero; Ron Acierno; Sandro Galea; Dean G Kilpatrick; Joel Gelernter Journal: J Anxiety Disord Date: 2008-12-25
Authors: Nathan A Kimbrel; Sandra B Morissette; Eric C Meyer; Roberta Chrestman; Robert Jamroz; Paul J Silvia; Jean C Beckham; Keith A Young Journal: Anxiety Stress Coping Date: 2014-11-14
Authors: Nathan A Kimbrel; Melanie E Garrett; Michelle F Dennis; Yutao Liu; Ilyas Patanam; Va Mid-Atlantic Mirecc Workgroup; Allison E Ashley-Koch; Michael A Hauser; Jean C Beckham Journal: Psychiatry Res Date: 2015-07-08 Impact factor: 3.222
Authors: Erika J Wolf; Ann M Rasmusson; Karen S Mitchell; Mark W Logue; Clinton T Baldwin; Mark W Miller Journal: Depress Anxiety Date: 2014-03-27 Impact factor: 6.505
Authors: Jeffrey S Simons; Raluca M Simons; Carol O'Brien; Scott F Stoltenberg; Jessica A Keith; Jaime A Hudson Journal: Addict Behav Date: 2016-09-04 Impact factor: 3.913
Authors: Ilan Wald; Kathryn A Degnan; Elena Gorodetsky; Dennis S Charney; Nathan A Fox; Eyal Fruchter; David Goldman; Gad Lubin; Daniel S Pine; Yair Bar-Haim Journal: JAMA Psychiatry Date: 2013-04 Impact factor: 21.596